US Edition
News from nhonews.com
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top nhonews.com News
Cancer · ChinaSAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)…See the Story
Innovent Presents Updated IBI363 Data in Colorectal Cancer at ASCO 2025
79% Center coverage: 33 sources
Shanghai, China · ShanghaiSHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the China…See the Story
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
90% Center coverage: 19 sources
Obesity · ChinaSAN FRANCISCO and SUZHOU, China, May 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major…See the Story
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
88% Center coverage: 18 sources
